Researchers from the UCLA Health Jonsson Comprehensive Cancer Center assembled the biobank from 126 patients diagnosed with more than 20 unique sarcoma subtypes treated at UCLA Health between February 2018 and May 2022.
The study found one FDA-approved drug therapy was effective on 59% of the biobank samples.
“Testing drugs with patient-derived tumor organoids has potential to help predict how a patient may respond to treatment,” Alice Soragni, PhD, an assistant professor of orthopedic surgery at UCLA, said in a Sept. 20 news release from the health system.
Read the study’s full findings here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
